First Report of Pembrolizumab Activity in KIT-Mutated Thymic Carcinoma

First Report of Pembrolizumab Activity in KIT-Mutated Thymic Carcinoma

The antitumor activity of immunotherapy is strongly influenced by the presence of driver gene mutations/translocations. For this reason, knowledge of the predictive value of specific genetic alterations in relation to anti-PD(L)1 activity is highly useful for the clinical decision making process in...

Full description

Saved in:
Bibliographic Details
Main Authors: Tommaso Martino De Pas, Giuseppe Giaccone, Chiara Catania, Fabio Conforti, Laura Pala, Periklis Mitsakis, Pierre-Yves Dietrich
Format: Article
Language:English
Published: MDPI AG 2025-01-01
Series:Current Oncology
Subjects:
thymic carcinoma
immunotherapy
KIT mutation
Online Access:https://www.mdpi.com/1718-7729/32/2/68
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items

Similar Items